Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Equity Bottom-Up

Bangkok Dusit Medical Services / Equity Bottom-Up

<ul><li>We downgrade our rating to Neutral (previously Outperform), with a more negative view on the fundamentals.</li><li>This is due to the expected 2024-26E EPS growth of just a +5% CAGR, weaker than the industry average of +7%.</li><li>On top of that, the stock price offers only 4% upside to the new fair value (FV).</li></ul>

We downgrade our rating to Neutral (previously Outperform), with a more negative view on the fundamentals.This is due to the expected 2024-26E EPS growth of just a +5% CAGR, weaker than the industry average of +7%.On top of that, the stock price offers only 4% upside to the new fair value (FV).

BDMS TB- Revised Down Earnings Forecasts to Reflect Weak Foreign Patient Numbers

<ul><li>We upgraded our rating to Outperform (previously Neutral), with a more positive outlook on the fundamentals.</li><li>The stock price has declined by 13% since our last report (2 months), widening the upside to +13% from the fair value of Bt28.75,based on a required return of 3.7%.</li><li>The two-year earnings performance is expected to grow well, with a 2024-26E CAGR of +8%, in line with the industry, which should see a CAGR of +9%.</li></ul>

We upgraded our rating to Outperform (previously Neutral), with a more positive outlook on the fundamentals.The stock price has declined by 13% since our last report (2 months), widening the upside to +13% from the fair value of Bt28.75,based on a required return of 3.7%.The two-year earnings performance is expected to grow well, with a 2024-26E CAGR of +8%, in line with the industry, which should see a CAGR of +9%.

Bangkok Dusit Medical Services Bdms - In-Line 3Q24 NP

<ul><li>We initiate coverage on BDMS with a Neutral rating and a 12- month fair value (12M FV) of Bt28.75, based on the earnings yield method with a required return of 3.7%.</li><li>The valuation metrics indicate long-term earnings growth at a CAGR of 8% in 2024-26E; meanwhile, the share price implies downside of -3%, and the tactical upside is very limited.</li><li>We like BDMS for its diversified revenue streams across various patient groups, its extensive network of hospitals, and its ability to cater to patients with health insurance, complex medical conditions, and the aging population through wellness services.</li></ul>

We initiate coverage on BDMS with a Neutral rating and a 12- month fair value (12M FV) of Bt28.75, based on the earnings yield method with a required return of 3.7%.The valuation metrics indicate long-term earnings growth at a CAGR of 8% in 2024-26E; meanwhile, the share price implies downside of -3%, and the tactical upside is very limited.We like BDMS for its diversified revenue streams across various patient groups, its extensive network of hospitals, and its ability to cater to patients with health insurance, complex medical conditions, and the aging population through wellness services.

Bangkok Dusit Medical Services - Expected Earnings Peak in 3Q24E Already Priced In

Thematic (Sector/Industry)

<ul><li>Although the market is likely to revise down EPS estimates following weaker-than- expected 3Q24 earnings, using the KTX implied EPS tool, we find that most sectors (accounting for over 80% of total market capitalization) have partially priced in the negative factors, which limits the downside risk.</li><li>In addition, the SET Index's correction of -0.8% (since the 3Q24 earnings announcements) has kept the market risk premium (MRP) stable at 4.213%, matching the lower bound of the trading buy range at an MRP of 4.21% (-1 S.D.).</li><li>This suggests that the SET is at a level where the risk-reward appears attractive. </li></ul>

Although the market is likely to revise down EPS estimates following weaker-than- expected 3Q24 earnings, using the KTX implied EPS tool, we find that most sectors (accounting for over 80% of total market capitalization) have partially priced in the negative factors, which limits the downside risk.In addition, the SET Index's correction of -0.8% (since the 3Q24 earnings announcements) has kept the market risk premium (MRP) stable at 4.213%, matching the lower bound of the trading buy range at an MRP of 4.21% (-1 S.D.).This suggests that the SET is at a level where the risk-reward appears attractive. 

Special Report: Investment Strategy Post-3Q24 Earnings Reports - NOVEMBER 21, 2024

<ul><li>KTX expects that the sale of Type A investment units of the Vayupak 1 Fund (VAYU1), scheduled for September 16-20, will meet the target of Bt150bn, with Bt50bn from individual investors and Bt100bn from institutional investors. (Note: these proportions may vary slightly depending on the authorities' discretion.)</li><li>The fund guarantees the principal and offers a minimum annual return of 3% (up to a maximum of 9%) over 10 years.</li><li>This attractive return, combined with high liquidity, is expected to encourage individual investors to shift funds from bank deposits to VAYU1 for better returns. </li></ul>

KTX expects that the sale of Type A investment units of the Vayupak 1 Fund (VAYU1), scheduled for September 16-20, will meet the target of Bt150bn, with Bt50bn from individual investors and Bt100bn from institutional investors. (Note: these proportions may vary slightly depending on the authorities' discretion.)The fund guarantees the principal and offers a minimum annual return of 3% (up to a maximum of 9%) over 10 years.This attractive return, combined with high liquidity, is expected to encourage individual investors to shift funds from bank deposits to VAYU1 for better returns. 

Special Report – Vayupak Fund 1 (VAYU1)

Thailand

Bangkok Dusit Medical Services Public Company Limited operates Bangkok General Hospital. The Hospital specializes in cardiovascular, lung, neurological, eye and genitourinary cancer, as well as physical therapy and medical imaging.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bangkok Dusit Medical Services (BDMS TB)

BDMS TB- Revised Down Earnings Forecasts to Reflect Weak Foreign Patient Numbers

We downgrade our rating to Neutral (previously Outperform), with a more negative view on the fundamentals. This is due to the expected 2024-26E EPS...

Krungthai XSpring

Bangkok Dusit Medical Services Bdms - In-Line 3Q24 NP

We upgraded our rating to Outperform (previously Neutral), with a more positive outlook on the fundamentals. The stock price has declined by 13%...

Krungthai XSpring

Bangkok Dusit Medical Services - Expected Earnings Peak in 3Q24E Already Priced In

We initiate coverage on BDMS with a Neutral rating and a 12- month fair value (12M FV) of Bt28.75, based on the earnings yield method with a...

Krungthai XSpring

Special Report: Investment Strategy Post-3Q24 Earnings Reports - NOVEMBER 21, 2024

Listed companies reported a combined net profit (SET EPS) of Bt208bn in 3Q24, which was approximately 8.5% below the consensus estimate.

Krungthai XSpring

Special Report – Vayupak Fund 1 (VAYU1)

KTX expects that the sale of Type A investment units of the Vayupak 1 Fund (VAYU1), scheduled for September 16-20, will meet the target of Bt150bn

Krungthai XSpring

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)